Advertisement

Loading...

Sino Biopharmaceutical Limited

1177.HKHKSE
Healthcare
Biotechnology
HK$6.30
HK$0.41(6.96%)
Hong Kong Market is Open • 11:46

Sino Biopharmaceutical Limited (1177.HK) Stock Competitors & Peer Comparison

See (1177.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1177.HKHK$5.71-1.89%105.3B39.27HK$0.15+1.53%
6160.HKHK$171.10+4.27%261.4B116.78HK$1.49N/A
1801.HKHK$86.05+8.38%147.1B161.32HK$0.53N/A
2269.HKHK$31.36-0.57%133.8B24.52HK$1.32N/A
9926.HKHK$132.80+7.36%116.3B-115.96-HK$1.09N/A
1530.HKHK$24.10+10.96%56.6B22.00HK$1.09+1.04%
9995.HKHK$99.00+11.74%51.7B-39.39-HK$2.39N/A
3759.HKHK$18.17+2.08%50.6B19.10HK$0.97+1.18%
2696.HKHK$69.80+5.76%39B41.69HK$1.72N/A
1877.HKHK$22.98+8.40%31.7B-23.73-HK$0.95N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1177.HK vs 6160.HK Comparison April 2026

1177.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1177.HK stands at 105.3B. In comparison, 6160.HK has a market cap of 261.4B. Regarding current trading prices, 1177.HK is priced at HK$5.71, while 6160.HK trades at HK$171.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1177.HK currently has a P/E ratio of 39.27, whereas 6160.HK's P/E ratio is 116.78. In terms of profitability, 1177.HK's ROE is +0.12%, compared to 6160.HK's ROE of +0.07%. Regarding short-term risk, 1177.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1177.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions